Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study.
R Ferreira A, Palha A, Correia L, Filipe P, Rodrigues V, Costa L, Miranda A, André R, Fernandes J, Gouveia J, Passos-Coelho JL, Moreira A, Brito M, Ribeiro J, Metzger-Filho O, U Lin N, Vaz-Luís I. R Ferreira A, et al. Among authors: brito m. Breast. 2016 Oct;29:68-73. doi: 10.1016/j.breast.2016.07.004. Epub 2016 Jul 25. Breast. 2016. PMID: 27468923
Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR, Palha A, Correia L, Filipe P, Rodrigues V, Miranda A, André R, Fernandes J, Gouveia J, Passos-Coelho JL, Moreira A, Brito M, Ribeiro J, Metzger-Filho O, Lin NU, Costa L, Vaz-Luis I. Ferreira AR, et al. Among authors: brito m. Breast. 2018 Feb;37:107-113. doi: 10.1016/j.breast.2017.11.003. Epub 2017 Nov 10. Breast. 2018. PMID: 29131988
The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn-Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Oing C, Bokemeyer C. Seidel C, et al. Among authors: brito m. Urol Oncol. 2019 Nov;37(11):809.e19-809.e25. doi: 10.1016/j.urolonc.2019.07.020. Epub 2019 Sep 5. Urol Oncol. 2019. PMID: 31494007
Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer.
Branco FP, Machado D, Silva FF, André S, Catarino A, Madureira R, Pinto JM, Godinho JP, Simões PD, Brito M, Casa-Nova M, Moreira AR, Passos-Coelho JL. Branco FP, et al. Among authors: brito m. Am J Transl Res. 2019 Sep 15;11(9):6110-6116. eCollection 2019. Am J Transl Res. 2019. PMID: 31632579 Free PMC article.
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL, Sweeney CJ, Connors JM. Fankhauser CD, et al. Among authors: brito m. Eur Urol Focus. 2021 Sep;7(5):1130-1136. doi: 10.1016/j.euf.2020.09.017. Epub 2020 Oct 6. Eur Urol Focus. 2021. PMID: 33032968 Free article.
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study.
Hentrich MU, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, Lesmeister F, Jurinovic V, Stoehr A, Heinzelbecker J, Krznaric I, Dieckmann KP, Necchi A, Maroto Rey P, Rockstroh JK, Brito M, Pfister D, Hoffmann C. Hentrich MU, et al. Among authors: brito m. Cancer. 2022 Jan 15;128(2):260-268. doi: 10.1002/cncr.33928. Epub 2021 Sep 30. Cancer. 2022. PMID: 34592009 Free article.
1,343 results